Physician profile
Sissy V John
NPI 1457516957
$1,084.71
in general payments reported to CMS, 2019-2025
22 companies · $460 in 2025
The $460 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $153 · 2024: $472 · 2025: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,084.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $143.98 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $122.29 | 2024-2025 | |
| Novo Nordisk INC | $112.10 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $95.75 | 2024-2025 | Veozah |
| Abbott Laboratories | $72.55 | 2024-2025 | Freestyle Libre 3, Octrode |
| Lundbeck LLC | $64.80 | 2024-2025 | Rexulti |
| Inspire Medical Systems, INC. | $61.84 | 2024-2025 | Inspire |
| Exact Sciences Corporation | $49.88 | 2024-2025 | Cologuard Collection Kit |
| Stryker Corporation | $44.72 | 2024 | Mild Device Kit |
| Ironshore Pharmaceuticals INC. | $44.58 | 2024 | |
| Janssen Pharmaceuticals, INC | $38.61 | 2024-2025 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.86 | 2024-2025 | Ofev, Jardiance |
| Medtronic, INC. | $30.68 | 2025 | Minimed 780g |
| Otsuka America Pharmaceutical, INC. | $23.86 | 2024 | Rexulti |
| Neurocrine Biosciences, INC. | $21.10 | 2024 | Ingrezza |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $20.12 | 2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $19.94 | 2024 | Farxiga |
| Sanofi-Aventis U.S. LLC | $19.83 | 2024 | |
| Pfizer INC. | $17.27 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $15.82 | 2024 | Ajovy |
| Amneal Pharmaceuticals LLC | $14.72 | 2025 | Unithroid |
| Tris Pharma INC | $14.41 | 2024 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sissy John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.